Randomized Phase II Study of SOL for Untreated Metastatic Colorectal Cancer
Randomized Phase II Study of SOL for Untreated Metastatic Colorectal Cancer
This is a randomized, multicenter study designed to evaluate the progression free survival of
 the SOL group (S-1, Leucovorin, and Oxaliplatin) compared with the mFOLFOX6 group (5-FU, l-LV
 and Oxaliplatin) as first-line treatment of patients with metastatic colorectal cancer.
Inclusion Criteria:

 -  Histologically proved adenocarcinoma (colorectal cancer).

 -  Age: 20 ≤ at enrollment.

 -  No prior treatment (ex. radiation therapy, chemotherapy, hormonal therapy) to advanced
 disease. Patients who received adjuvant chemotherapy more than 180 days before
 enrollment can be allowed but those who received S-1 or Oxaliplatin containing
 treatment shall be excluded.

 -  At least one measurable lesion by RECIST criteria

 Exclusion Criteria:

 -  Serious drug hypersensitivity.

 -  Prior history of peripheral neuropathy.

 -  Diarrhea .

 -  Simultaneously active double cancer.